Literature DB >> 30198467

Ethical Considerations in Ending Exploratory Brain-Computer Interface Research Studies in Locked-in Syndrome.

Eran Klein, Betts Peters, Matt Higger.   

Abstract

Brain-computer interface (BCI) is a promising technology for restoring communication in individuals with locked-in syndrome (LIS). BCI technology offers a potential tool for individuals with impaired or absent means of effective communication to use brain activity to control an output device such as a computer keyboard. Exploratory studies of BCI devices for communication in people with LIS are underway. Research with individuals with LIS presents not only technological challenges, but ethical challenges as well. Whereas recent attention has been focused on ethical issues that arise at the initiation of studies, such as how to obtain valid consent, relatively little attention has been given to issues at the conclusion of studies. BCI research in LIS highlights one such challenge: How to decide when an exploratory BCI research study should end. In this article, we present the case of an individual with presumed LIS enrolled in an exploratory BCI study. We consider whether two common ethical frameworks for stopping randomized clinical trials-equipoise and nonexploitation-can be usefully applied to elucidating researcher obligations to end exploratory BCI research. We argue that neither framework is a good fit for exploratory BCI research. Instead, we apply recent work on clinician-researcher fiduciary obligations and in turn offer some preliminary recommendations for BCI researchers on how to end exploratory BCI studies.

Entities:  

Keywords:  Brain–computer interface (BCI); exploratory research; locked-in syndrome (LIS); randomized clinical trials

Mesh:

Year:  2018        PMID: 30198467      PMCID: PMC8219386          DOI: 10.1017/S0963180118000154

Source DB:  PubMed          Journal:  Camb Q Healthc Ethics        ISSN: 0963-1801            Impact factor:   1.284


  33 in total

Review 1.  Trust based obligations of the state and physician-researchers to patient-subjects.

Authors:  P B Miller; C Weijer
Journal:  J Med Ethics       Date:  2006-09       Impact factor: 2.903

2.  A note on ethical aspects of BCI.

Authors:  Pim Haselager; Rutger Vlek; Jeremy Hill; Femke Nijboer
Journal:  Neural Netw       Date:  2009-07-07

3.  Varieties of the locked-in syndrome.

Authors:  G Bauer; F Gerstenbrand; E Rumpl
Journal:  J Neurol       Date:  1979-08       Impact factor: 4.849

4.  Severely affected ALS patients have broad and high expectations for brain-machine interfaces.

Authors:  Yu Kageyama; Masayuki Hirata; Takufumi Yanagisawa; Toshio Shimokawa; Jinichi Sawada; Shayne Morris; Nozomi Mizushima; Haruhiko Kishima; Osamu Sakura; Toshiki Yoshimine
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-09-10       Impact factor: 4.092

5.  Recursive Bayesian Coding for BCIs.

Authors:  Matt Higger; Fernando Quivira; Murat Akcakaya; Mohammad Moghadamfalahi; Hooman Nezamfar; Mujdat Cetin; Deniz Erdogmus
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2016-07-13       Impact factor: 3.802

6.  Neuronal ensemble control of prosthetic devices by a human with tetraplegia.

Authors:  Leigh R Hochberg; Mijail D Serruya; Gerhard M Friehs; Jon A Mukand; Maryam Saleh; Abraham H Caplan; Almut Branner; David Chen; Richard D Penn; John P Donoghue
Journal:  Nature       Date:  2006-07-13       Impact factor: 49.962

7.  Principles of early stopping of randomized trials for efficacy: a critique of equipoise and an alternative nonexploitation ethical framework.

Authors:  David Buchanan; Franklin G Miller
Journal:  Kennedy Inst Ethics J       Date:  2005-06

8.  The real problem with equipoise.

Authors:  Winston Chiong
Journal:  Am J Bioeth       Date:  2006 Jul-Aug       Impact factor: 11.229

9.  The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials.

Authors:  Daniel P Sulmasy; Alan B Astrow; M Kai He; Damon M Seils; Neal J Meropol; Ellyn Micco; Kevin P Weinfurt
Journal:  Cancer       Date:  2010-08-01       Impact factor: 6.860

10.  Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design.

Authors:  Chunqin Deng; Kim Hanna; Vera Bril; Marinos C Dalakas; Peter Donofrio; Pieter A van Doorn; Hans-Peter Hartung; Ingemar S J Merkies
Journal:  J Neurol       Date:  2011-08-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.